Tonix Pharmaceuticals stock halted ahead of FDA approval news
Ingredion Inc (NASDAQ:INGR) President and CEO James P. Zallie sold 36,287 shares of common stock on August 12, 2025, for approximately $4.5 million. The shares were sold at a weighted average price of $126.523, with individual sales prices ranging from $126.50 to $126.60. The transaction comes as Ingredion, currently valued at $8.08 billion, trades near its 52-week low with a P/E ratio of 12.1, suggesting potential undervaluation according to InvestingPro analysis.
On the same day, Zallie also exercised options to acquire a total of 224,838 shares of Ingredion common stock. These transactions involved two separate option grants: one for 96,316 shares at an exercise price of $91.85, and another for 128,522 shares at an exercise price of $88.35, totaling $20,201,543.
Additionally, Zallie disposed of 188,551 shares of common stock to cover applicable taxes and the exercise price for the stock options. These shares were disposed of at prices ranging from $126.46 to $126.54, for a total value of $23,852,712.
Following these transactions, Zallie directly owns 86,415.895 shares of Ingredion Inc . common stock.
In other recent news, Ingredion Incorporated reported its second-quarter earnings for 2025, revealing a mixed financial outcome. The company surpassed earnings per share (EPS) expectations with a reported EPS of $2.87, compared to the forecasted $2.80. However, Ingredion’s revenue fell short of projections, reaching $1.8 billion against an anticipated $1.89 billion. This revenue shortfall has raised concerns among investors. Despite the positive EPS results, the company’s stock experienced a decline. These developments highlight the importance of revenue performance in investor assessments. The financial results reflect current market conditions and the challenges faced by Ingredion.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.